Autoimmune disease
MONDO:0007179A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to their own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).
Also known as: autoimmune disease, autoimmune disease or disorder, autoimmune disorder, disease, autoimmune, autoimmune hypersensitivity disease, hypersensitivity reaction type II disease
4033 clinical trials for this condition and its sub-types, 313 tagged with Autoimmune disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Autoimmune disease
-
Autoimmune disorder of the nervous system 47 trials · 1,060 incl. sub-types
4 sub-types
- Autoimmune disorder of central nervous system 2 trials · 874 incl. sub-types Sub-types →
- Autoimmune disorder of peripheral nervous system 0 trials · 194 incl. sub-types Sub-types →
- Pediatric acute-onset neuropsychiatric syndrome 8 trials · 10 incl. sub-types Sub-types →
- Autoimmune retinopathy 0 trials
-
Autoimmune disorder of gastrointestinal tract 0 trials · 936 incl. sub-types
7 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Celiac disease 79 trials Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune enteropathy 2 trials · 11 incl. sub-types Sub-types →
- Autoimmune gastritis 3 trials
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related sclerosing cholangitis 0 trials
-
Autoimmune disorder of endocrine system 1 trial · 925 incl. sub-types
13 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Autoimmune thyroid disease 8 trials · 62 incl. sub-types Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune polyendocrinopathy 3 trials · 11 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- Autoimmune hypoparathyroidism 0 trials · 8 incl. sub-types Sub-types →
- Autoimmune pancreatitis 3 trials Sub-types →
- Autoimmune primary ovarian failure 1 trial
- IgG4-related sclerosing cholangitis 0 trials
- Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome 0 trials
- Autoimmune oophoritis 0 trials
- Insulin autoimmune syndrome 0 trials
- Primary hypophysitis 0 trials Sub-types →
-
CNS demyelinating autoimmune disease 5 trials · 853 incl. sub-types
1 sub-type
- Multiple sclerosis 765 trials · 852 incl. sub-types Sub-types →
-
Autoimmune disorder of musculoskeletal system 0 trials · 795 incl. sub-types
3 sub-types
- Rheumatoid arthritis 576 trials · 795 incl. sub-types Sub-types →
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Neonatal dermatomyositis 0 trials
-
Lupus erythematosus 39 trials · 548 incl. sub-types
3 sub-types
- Systemic lupus erythematosus 516 trials · 522 incl. sub-types Sub-types →
- Cutaneous lupus erythematosus 38 trials · 46 incl. sub-types Sub-types →
- Drug-induced lupus erythematosus 1 trial
-
Scleroderma 47 trials · 305 incl. sub-types
3 sub-types
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Localized scleroderma 14 trials · 15 incl. sub-types Sub-types →
- Neonatal scleroderma 0 trials
-
Autoimmune disorder of exocrine system 0 trials · 196 incl. sub-types
3 sub-types
- Sjogren syndrome 166 trials
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Benign lymphoepithelial lesion of salivary gland 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Evans syndrome 19 trials
-
Vitiligo 100 trials
3 sub-types
- Generalized vitiligo 16 trials
- Alopecia universalis onychodystrophy vitiligo 0 trials
- Trichrome vitiligo 0 trials
-
Antiphospholipid syndrome 58 trials · 59 incl. sub-types
4 sub-types
- Primary antiphospholipid syndrome 4 trials
- Catastrophic antiphospholipid syndrome 1 trial
- Familial antiphospholipid syndrome 0 trials
- Secondary antiphospholipid syndrome 0 trials Sub-types →
-
Autoimmune bullous skin disease 7 trials · 55 incl. sub-types
11 sub-types
- Pemphigus 20 trials · 27 incl. sub-types Sub-types →
- Bullous pemphigoid 18 trials
- Mucous membrane pemphigoid 5 trials · 9 incl. sub-types Sub-types →
- Acquired epidermolysis bullosa 3 trials
- Dermatitis herpetiformis 1 trial Sub-types →
- Pemphigoid 1 trial
- IgA pemphigus 0 trials
- Anti-p200 pemphigoid 0 trials
- Linear IgA Dermatosis 0 trials
- Paraneoplastic pemphigus 0 trials
- Subcorneal pustular dermatosis 0 trials
-
Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types
14 sub-types
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related kidney disease 1 trial
- IgG4-related retroperitoneal fibrosis 1 trial Sub-types →
- IgG4-related aortitis 0 trials
- IgG4-related mediastinitis 0 trials
- IgG4-related mesenteritis 0 trials
- IgG4-related ophthalmic disorder 0 trials Sub-types →
- IgG4-related pachymeningitis 0 trials
- IgG4-related sclerosing cholangitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- IgG4-related thyroid disease 0 trials
- Cutaneous pseudolymphoma 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
- Primary cutaneous plasmacytosis 0 trials
-
Rheumatic fever 16 trials
-
Overlapping connective tissue disease 2 trials · 15 incl. sub-types
2 sub-types
- Mixed connective tissue disease 15 trials
- MASS syndrome 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
Type III hypersensitivity disease 3 trials · 6 incl. sub-types
2 sub-types
- Serum sickness 3 trials
- Arthus reaction 0 trials
-
Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types
7 sub-types
- Autoimmune inner ear disease 2 trials
- Autoimmune uveitis 2 trials
- Cogan syndrome 0 trials
- IgG4-related dacryoadenitis and sialadenitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- Autoimmune retinopathy 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
-
Cryoglobulinemia 3 trials
1 sub-type
- Cryofibrinogenemia 0 trials Sub-types →
-
Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types
6 sub-types
- Chilblain lupus 1 trial · 3 incl. sub-types Sub-types →
- Libman-Sacks endocarditis 0 trials
- Autoimmune atherosclerosis 0 trials
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Autoimmune vasculitis 0 trials Sub-types →
- Rheumatic pulmonary valve disease 0 trials
-
Susac syndrome 2 trials
-
Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types
-
Phacolytic glaucoma 1 trial
-
Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types
6 sub-types
- Neonatal lupus erythematosus 1 trial
- Neonatal antiphospholipid syndrome 0 trials
- Neonatal autoimmune hemolytic anemia 0 trials
- Neonatal dermatomyositis 0 trials
- Neonatal scleroderma 0 trials
- Transient neonatal myasthenia gravis 0 trials
-
Jaccoud syndrome 0 trials
-
Kimura disease 0 trials
-
Reynolds syndrome 0 trials
-
Autoimmune glomerulonephritis 0 trials
-
Autoimmune urticaria 0 trials
-
Euthyroid Graves orbitopathy 0 trials
-
Tempi syndrome 0 trials
Most studied deeper sub-types
-
Experimental CAR-T therapy takes aim at Hard-to-Treat scleroderma
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own modified immune cells to target and destroy certain B cells tha…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could CAR-T cells tame tough lupus kidney disease?
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control Stopped earlyThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New shot aims to keep insulin flowing in type 1 diabetes
Disease control Stopped earlyThis study tests a drug called Diamyd in people aged 12 to 29 who were recently diagnosed with type 1 diabetes and have a specific genetic type (HLA DR3-DQ2). The goal is to see if Diamyd can help the body keep making its own insulin, which could improve blood sugar control and r…
Phase 3 • Sponsor: Diamyd Medical AB • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for nerve disease: batoclimab safety trial expands
Disease control Stopped earlyThis study checks the long-term safety of a drug called batoclimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 108 people who finished an earlier batoclimab study will get weekly injections fo…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new antibody calm the immune attack in CIDP?
Disease control Stopped earlyThis trial is testing whether an experimental drug called batoclimab can help adults with active chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system damages nerves, causing weakness and disability. Participants receive either batoclimab o…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control Stopped earlyThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Anti-Inflammatory drug studied for PANDAS-Related OCD in kids
Disease control Stopped earlyThis study tested the anti-inflammatory drug naproxen sodium for treating obsessive-compulsive symptoms in children aged 6-15 with PANDAS, a condition linked to strep infections. The trial was double-blind and placebo-controlled, but it was terminated early after enrolling only 2…
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
CRISPR's diabetes cell therapy trial ends early
Disease control Stopped earlyThis early-stage study tested a new treatment called VCTX211 for people with type 1 diabetes. The goal was to see if implanting these special cells could help the body make insulin and reduce the need for insulin shots. Only 5 people took part, and the study was stopped early. Th…
Phase 1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Sjögren's drug trial halted: what happened?
Disease control Stopped earlyThis study tested an experimental drug called HZN-1116 in 209 people with Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The goal was to see if the drug could reduce disease activity and symptoms. The trial was terminated early, so results may not be availa…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Batoclimab shows promise for thyroid eye disease in extension study
Disease control Stopped earlyThis study is for people who finished earlier trials of batoclimab for thyroid eye disease. It has two parts: one watches how long benefits last without treatment, and the other gives batoclimab to see if it helps more patients. The goal is to see if the drug can control eye bulg…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Melatonin trial for MS halted early – what we know
Disease control Stopped earlyThis study tested whether adding melatonin to the standard drug ocrelizumab could safely slow disability in people with progressive primary multiple sclerosis. The trial was terminated early, so results are limited. Participants were adults aged 18–65 with this type of MS.
Phase 1/2 • Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug peresolimab tested for rheumatoid arthritis – study ends early
Disease control Stopped earlyThis study tested peresolimab, an experimental drug, in 491 adults with moderately-to-severely active rheumatoid arthritis who had not responded well to other treatments. The goal was to see if peresolimab could reduce joint pain and swelling better than a placebo. However, the s…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Brain fatigue after thyroid disease: immune system may be to blame
Knowledge-focused Stopped earlyThis study investigates why some people with Graves' disease continue to feel mentally fatigued even after their thyroid levels return to normal. Researchers will compare blood and spinal fluid from 180 participants—60 with mental fatigue, 60 without, and 60 healthy controls—to f…
Sponsor: Vastra Gotaland Region • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Biopsy tolerance study ends early – what we know
Knowledge-focused Stopped earlyThis study aimed to understand how well patients tolerate biopsies for autoimmune diseases and whether they feel properly informed. It planned to enroll 505 people but was terminated early. The results may help improve patient experience with these common procedures.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused Stopped earlyThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC